GlassScriptPhysician profile
Robert T Schooley
NPI 1346298502
$57,018.87
in general payments reported to CMS, 2019-2025
8 companies · $850 in 2025
The $850 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $3,163 · 2021: $4,927 · 2022: $8,861 · 2023: $14K · 2024: $17.67 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,216 · Consulting Fee: $5,688 · Food and Beverage: $17.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,216.00 |
| Consulting Fee | $5,687.50 |
| Food and Beverage | $17.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25,146.95 | 2019 | |
| Abbvie INC. | $9,487.50 | 2020-2022 | |
| Veru INC. | $9,216.00 | 2023 | |
| Merck Sharp & Dohme LLC | $7,501.25 | 2021-2025 | Lagevrio |
| Takeda Pharmaceuticals U.S.A., INC. | $4,837.50 | 2023 | |
| Pfizer INC. | $800.00 | 2022 | |
| Viiv Healthcare Company | $17.67 | 2024 | Cabenuva |
| Paratek Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.